FDA OKs Combination for Low-Grade Serous Ovarian Cancer

FDA OKs Combination for Low-Grade Serous Ovarian Cancer

(MedPage Today) -- The FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for the treatment of adults with KRAS-mutated, recurrent low-grade serous ovarian cancer who have received prior...

FDA Grants First-Ever Approval for Treatment of KRAS-Mutated Recurrent LGSOC

Verastem Oncology announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for the AVMAPKI FAKZYNJA CO-PACK, which includes avutometinib capsules and … FDA Grants First-Ever Approval for Treatment of KRAS-Mutated Recurrent LGSOC Read More » The post FDA Grants First-Ever Approval for Treatment of KRAS-Mutated Recurrent LGSOC first appeared on GeneOnline News. The post FDA Grants First-Ever Approval for Treatmen…

FDA Approves Avutometinib/Defactinib for Adults With KRAS-Mutated Recurrent LGSOC

With this approval, avutometinib/defactinib has become the first and only FDA-approved treatment for patients with recurrent low-grade serous ovarian cancer (LGSOC).

Dr Monk the FDA Approval of Avutometinib and Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Bradley Monk, MD, FACOG, FACS, discusses the FDA’s accelerated approval of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

Avutometinib/Defactinib Earns FDA Accelerated Approval for KRAS+ LGSOC

The FDA has granted accelerated approval to avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer.

FDA Approves Avmapki Fakzynja Co-pack for KRAS Serous Ovarian Cancer

Treatment with the Avmapki Fakzynja Co-pack received accelerated FDA approval for previously treated low-grade serous ovarian cancer with KRAS mutations.